Abstract:Mortality rates from thyroid cancer have fallen significantly in recent decades, almost certainly as the result of earlier diagnosis and improved treatment of differentiated (papillary and follicular) thyroid cancer. Enhanced survival is likely a result of early diagnosis and therapy applied at a disease stage when treatment is most effective. In the United States and Europe, most patients at high risk for relapse and death from thyroid cancer are treated with total or near-total thyroidectomy and receive radioiodine ablation of residual normal or malignant thyroid tissue, followed by treatment with thyroid hormone, a strategy that cures more than 80% of patients. Still, some die of the disease and nearly 15% have local recurrences, while another 5% to 10% develop distant metastases. Over 50% of recurrences appear in the first five years, but distant metastases may surface years, and sometimes decades, after initial therapy. Much has been learned about risk stratification to predict recurrence and death from thyroid cancer but individual patients continue to have adverse outcomes not always foreseen by a low tumor stage. Follow-up must accordingly be meticulous and prolonged. The National Cancer Center Network (NCCN) has recently established consensus practice guidelines that give explicit advice about the diagnosis and management of benign and malignant thyroid tumors, including paradigms for long-term follow-up and the treatment of recurrent disease. The guidelines confirm that diagnostic scanning with 131I and measurement of serum thyroglobulin (Tg) levels are the mainstay of follow-up, offering the opportunity to detect recurrent or persistent cancer at very early stages. These guidelines advocate TSH-stimulated serum Tg measurements, done either during thyroid hormone withdrawal or stimulation with recombinant human TSH (rhTSH, Thyrogen), that often identify the presence of cancer well before diagnostic whole-body scanning or other imaging studies can spot the tumor, which offers the opportunity to treat recurrent disease at an early stage. The use of rhTSH adds a new dimension to long-term follow-up that avoids putting patients through the symptoms of hypothyroidism, and offers the opportunity to follow some patients with rhTSH-stimulated serum Tg levels without performing 131I whole-body scans. A multicenter international study has shown that serum Tg measurements alone are not as sensitive in the identification of patients with persistent or recurrent tumor as are rhTSH-stimulated serum Tg determinations. Although not yet approved for preparation of patients for 131I therapy, rhTSH has been used successfully in a compassionate use program for this purpose in a relatively large number of patients. Formal clinical investigations now planned to provide guidelines for the use of rhTSH for therapeutic 131I portend a new set of effective therapeutic paradigms for the management of differentiated thyroid cancer.

Summary and update on the management of differentiated thyroid cancer in 2023

Current practice in patients with differentiated thyroid cancer

Thyroid cancer, recent advances in diagnosis and therapy

La prise en charge des cancers médullaires de la thyroïde en 2024

Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice

State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.

Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo

Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma

Management of differentiated thyroid carcinoma with bone metastasis: a case report and review of the Chinese literature

Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma

Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy

Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective

Using Recombinant Human TSH in the Management of Well-Differentiated Thyroid Cancer: Current Strategies and Future Directions

Controversies in the management of intermediate-risk differentiated thyroid cancer

Thyroid surgery for differentiated thyroid cancer - recent advances and future directions

Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

Postsurgical Management of Differentiated Thyroid Cancer in China.

Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus

The Fundamental Role of Radioiodine in the Management of Thyroid Cancer

Update on the Molecular Diagnosis and Targeted Therapy of Thyroid Cancer